Attorneys for 15 plaintiffs have asked the Joint Panel on Multidistrict Litigation to consolidate Dupixent lawsuits into a single federal MDL, arguing that the growing number of cases share common factual questions related to alleged links between Dupixent and cutaneous T-cell lymphoma. Separately, new biosimilar development activity in Europe highlights how the Dupixent ecosystem continues to expand even as U.S. litigation pressure builds.
February 13 2026 Attorneys Ask JPML to Create a Dupixent MDL
A motion filed with the JPML seeks centralized federal coordination for lawsuits alleging that Dupixent (dupilumab) caused plaintiffs to develop cutaneous T-cell lymphoma. Attorneys have requested that the potential MDL be assigned to the Northern District of Georgia, a venue they argue is appropriate for managing common discovery and early pretrial rulings.
If approved, the MDL would create a single federal forum for coordinated pretrial proceedings such as:
- document discovery
- expert scheduling
- bellwether trial planning
- early motions practice
This step is significant because it signals the litigation is moving from isolated cases into a structured federal process designed for scale.
What an MDL Would Change for Dupixent Cases
An MDL does not merge lawsuits into one case and it does not automatically create a settlement. It does, however, concentrate:
- core fact discovery
- corporate document production
- early expert battles
- key rulings that influence many cases at once
For claimants, an MDL often becomes the central arena where the litigation’s momentum is set. For defendants, it generally creates a single coordinated track for defense strategy, rather than fighting procedural battles across multiple courts.
Why This Filing Matters Now
This motion arrives while Dupixent remains widely prescribed for multiple inflammatory conditions and continues to move into additional patient populations. That broader exposure context matters because MDL arguments often emphasize shared issues such as:
- what the manufacturers knew and when
- how risks were evaluated internally
- whether labeling and safety communications were adequate
- how adverse event signals were monitored and remediated
This update is distinct from earlier procedural developments. For example, a federal court recently extended deadlines in a wrongful death Dupixent case, another likely sign that early litigation tracks are still forming. See the update on court deadlines in the Dupixent wrongful death case.
February 2, 2026, Biosimilar Dupixent Testing Moves Forward in Europe
In a separate development, a South Korean company received permission to move forward with biosimilar testing in Europe, with a clinical trial involving Dupixent and a bioequivalent product scheduled to begin in early February 2026.
Biosimilar development can matter in parallel with litigation for a simple reason: it reflects long-term commercial expectations around a drug’s market footprint. While biosimilar trials are not evidence of wrongdoing, they can coincide with increased scrutiny as usage expands and more post-marketing safety questions surface.
Avoiding Content Overlap With CTCL Background Coverage
This post is focused on litigation structure and timeline. If you want the deeper background on CTCL, misdiagnosis concerns, and research summaries, that information is already covered in your separate explainer on what research says about Dupixent and CTCL risk.
What This Means for People Following the Dupixent Litigation
If the JPML approves MDL consolidation, future updates will likely focus on:
- where the MDL is assigned
- leadership appointments for plaintiffs’ counsel
- initial case management orders
- early discovery deadlines
- bellwether selection framework
For people tracking eligibility and claim criteria in one place, the best next step is to review Dupixent lawsuit eligibility and monitor updates as the federal process develops.
Conclusion
The JPML motion is a clear signal that Dupixent CTCL litigation is entering a more mature phase, where centralized discovery and coordinated rulings can accelerate how quickly the broader case picture develops. At the same time, biosimilar activity in Europe underscores that Dupixent’s market expansion continues even as U.S. legal challenges intensify.
Add Comment